Biomx Ltd is a biotechnology company focused on developing innovative therapies that harness the power of bacteriophage, a type of virus that specifically targets and kills bacteria. The company primarily aims to treat diseases caused by specific bacterial infections, particularly those that are resistant to traditional antibiotics. By utilizing phage-based treatments, Biomx is working to address significant medical challenges in various conditions, including gastrointestinal disorders and other diseases driven by harmful bacteria, with the ultimate goal of improving patient outcomes and enhancing the overall landscape of antimicrobial therapies. Read More
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Antibiotic resistance has become one of medicine’s most urgent challenges. The CDC estimates that resistant infections cause ~35,000 deaths each year in the U.S. and more than 1 million globally - a number projected to rise sharply over the next 25 years. Traditional drug development is struggling to keep pace, forcing healthcare systems to look beyond antibiotics altogether.
Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their outstanding shares is at $87.2 million.
BiomX Inc (PHGE) reports Q2 2025 earnings surprise with EPS of $0.19 vs. expected loss, sparking a 142% pre-market surge. Phase 2 results for BX211 show promising efficacy in diabetic foot osteomyelitis treatment.
